This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
CMC Strategy Forum Japan 2019
Share |

 

On behalf of the CASSS Board of Directors and the CMC Strategy Forum Global Steering Committee, I would like to extend to you a warm welcome to the eighth meeting of the CMC Strategy Forum Japan 2019 that will be held 11-12 December in Tokyo, Japan.  


We are very pleased that with the strong support from the Pharmaceuticals and Medical Devices Agency (PMDA, Japan), as well as the Japan Pharmaceutical Manufacturers Association (JPMA), and with the continued organization by CASSS and the support from the United States Food and Drug Administration, that we are continuing with the CMC Strategy Forum Japan 2019. Our 2018 Forum continued to be a great success and included participation from nine regulatory agencies, twelve countries and 48 companies and academic institutions, enabling an in-depth discussion of global CMC issues with special emphasis on Japan and Asia-Pacific. The Forum will follow the established model of the CMC Forum series with focus on topics and regulatory updates relevant for Japan and Asia and will feature an opening regulatory session that will include presentations from PMDA, US FDA, EMA and Health Canada. In addition, there will be an ASEAN regulatory updates session; the following regulatory agencies have been invited to participate: ASEAN; National Agency of Drug and Food Control, Indonesia; Ministry of Food and Drug Safety (MFDS), Republic of Korea; National Pharmaceutical Regulatory Agency (NPRA), Malaysia; Ministry of Public Health, FDA Thailand; and Drug Administration of Vietnam. The technical sessions will include discussions on advanced-type antibody products (bispecific, drug conjugate) and technologies related to viral validation and an update about the ICH Q5A revision. 

With this exciting program, I would like to extend to you an invitation to attend and participate actively in making this Forum a great success.

Wassim Nashabeh
On behalf of the CMC Strategy Forum Global Steering Committee 




 

 Want more information? Check out the "More in this Section" dropdown box at the top of the page!
Or contact CASSS at 510-428-0740 or info@casss.org

 


 


CMC Strategy Forum Japan is supported by the Pharmaceuticals and Medical Devices Agency, Japan
and the Japan Pharmaceutical Manufacturers Association






                                       

Membership Software Powered by YourMembership  ::  Legal